

ASX Announcement

Race Oncology Investor Briefing Details – Hong Kong

17 September 2025 – Race Oncology Limited (“Race”) is pleased to announce venue and agenda details for the special investor lunch briefing being held in Hong Kong on 14 October 2025.

As part of the interactive session, Dr Pete Smith, Executive Chairman and Dr Daniel Tillett, Managing Director and Chief Executive Officer will present an overview of the company and an update on the company’s clinical development plans. Discussion will also cover the recent opening of clinical trial sites in Hong Kong - an important milestone in the global expansion of the program. Investors will be invited to ask questions throughout the lunch.

Event Details

Date: Tuesday, 14 October 2025

Time: 12:15pm for a 12:30pm start (Hong Kong time)

Location: Library Room
Grand Hyatt Hotel
1 Harbour Road
Wan Chai, Hong Kong

Dress: Smart casual or business

RSVP: Places are strictly limited so please RSVP by 26 September 2025 to:

jane.lowe@irdepartment.com.au

Please advise any dietary requirements.

The Race team looks forward to meeting all those who can join us on the day.

-ENDS-



About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile.

Race is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on combinations with anthracycline, where we aim to deliver both cardioprotection and enhanced anticancer activity in solid tumour indications. Race is also exploring the use of RC220 as a low intensity treatment for acute myeloid leukaemia and other cancers.

Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub announcements.raceoncology.com

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au